Medtronic plc (MDT)
Medtronic plc (MDT) Q1 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q1 2025 Earnings Conference Call August 20, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim Chief Financial Officer Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Conference Call Participants Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Travis Steed - Bank of America Securities Danielle Antalffy - UBS Securities Lawrence Biegelsen - Wells Fargo David Rescott - Baird Equity Research Matt Taylor - Jefferies David Roman - Goldman Sachs Jayson Bedford - Raymond James Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning and welcome to another Medtronic Earnings Day. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us this morning for our Fiscal 2025 First Quarter Video Earnings Webcast.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
Medtronic (MDT) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.20 per share a year ago.
Medtronic lifts profit forecast on medical devices demand, new launches
Medtronic slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its new launches.
Medtronic's stock gains after profit and sales topped forecasts, and the full-year outlook was nudged up
Shares of Medtronic PLC MDT, +0.26% gained 0.8% in premarket trading Tuesday, after the cardiovascular and medical surgical products company topped fiscal first-quarter profit and sales expectations and nudged up its full-year outlook. Net income for the quarter to July 26 rose to $1.04 billion, or 80 cents a share, from $791 million, or 59 cents a share, in the year-ago period.
Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?
Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.
Medtronic: Healthy Vital Signs Heading Into Earnings
Medtronic stock underperformed the market, up only 4% in the past year. The options market predicts a 3.3% stock price swing post-earnings. Mid-single-digit EPS growth, rising dividends, and historically high yield for Medtronic are positive factors.
Medtronic: Still A Buy Before Earnings
Medtronic is a strong option for investors seeking both low volatility and consistent dividend growth. I am quite positive about recent developments related to new crucial FDA approvals. Various valuation approaches suggest that the current share price is attractive.
Is An Earnings Beat In The Cards For Medtronic Stock?
Medtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates.
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Seeking Clues to Medtronic (MDT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended July 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Medtronic (MDT) stood at $82.27, denoting a +1.33% change from the preceding trading day.
